Lefebvre Megan E, Hughes Christine A, Yasui Yutaka, Saunders L Duncan, Houston Stan
University of Alberta.
Can J Public Health. 2014 Jul 11;105(4):e251-7. doi: 10.17269/cjph.105.4254.
The HIV/AIDS epidemic disproportionately involves socially vulnerable populations. Since 2001, the proportion of foreign-born patients served by the Northern Alberta HIV Program has increased. Our study aimed to evaluate antiretroviral therapy (ART) outcomes among HIV-infected foreign-born patients in northern Alberta, Canada, prescribed once-daily ART.
We utilized a two-part retrospective cohort study to compare ART outcomes of foreign-born and Canadian-born Aboriginal patients compared to Canadian-born non-Aboriginal patients. Part 1 utilized logistic regression to compare the odds of experiencing initial virological suppression of foreign-born (40%) and Canadian-born Aboriginal patients (27%) compared with Canadian-born non-Aboriginal patients (33%). Part 2 used survival analysis to compare the rate of ART failure by country of origin among patients who achieved initial virological suppression in Part 1.
Our study sample included 322 treatment-naïve patients (122 foreign-born). For Part 1, 261 patients achieved initial virological suppression within six months of initiating ART. After controlling for age, treatment regimen, HIV risk exposure, and calendar year compared to Canadian-born non-Aboriginal patients, the odds of achieving initial virological suppression were significantly lower for Canadian-born Aboriginal patients (OR=0.44, 95% CI: 0.20-0.96); and similar for foreign-born patients (OR=0.76, 95% CI: 0.33-1.73). Part 2 included 261 patients who were followed for 635.1 person-years. Adjusting for age, sex, baseline CD4 cell count, and drug regimen, compared to Canadian-born non-Aboriginal patients, Canadian-born Aboriginal and foreign-born patients had similar rates of virological failure after achieving initial virological suppression (HR=1.54, 95% CI: 0.38-6.18; HR=0.49, 95% CI: 0.11-2.20, respectively).
Our study indicated that ART outcomes among Alberta-based foreign-born patients are similar to those among Canadian-born non-Aboriginal patients. Our results, however, suggested that Canadian-born Aboriginal patients had poorer treatment outcomes compared to Canadian-born non-Aboriginal patients. It is imperative, therefore, that clinicians, researchers and community members better understand reasons for poor ART outcomes among Canadian-born Aboriginal patients in northern Alberta.
艾滋病毒/艾滋病疫情在社会弱势群体中更为严重。自2001年以来,北艾伯塔省艾滋病毒项目所服务的外国出生患者比例有所增加。我们的研究旨在评估加拿大艾伯塔省北部感染艾滋病毒的外国出生患者接受每日一次抗逆转录病毒疗法(ART)的治疗效果。
我们采用两部分回顾性队列研究,比较外国出生患者、加拿大出生的原住民患者与加拿大出生的非原住民患者的ART治疗效果。第1部分采用逻辑回归比较外国出生患者(40%)和加拿大出生的原住民患者(27%)与加拿大出生的非原住民患者(33%)实现初始病毒学抑制的几率。第2部分使用生存分析比较第1部分中实现初始病毒学抑制的患者按原籍国划分的ART治疗失败率。
我们的研究样本包括322名初治患者(122名外国出生)。对于第1部分,261名患者在开始ART治疗的6个月内实现了初始病毒学抑制。与加拿大出生的非原住民患者相比,在控制了年龄、治疗方案、艾滋病毒风险暴露和日历年之后,加拿大出生的原住民患者实现初始病毒学抑制的几率显著更低(比值比=0.44,95%置信区间:0.20 - 0.96);外国出生患者的几率相似(比值比=0.76,95%置信区间:0.33 - 1.73)。第2部分包括261名患者,随访了635.1人年。在调整年龄、性别、基线CD4细胞计数和药物治疗方案后,与加拿大出生的非原住民患者相比,加拿大出生的原住民患者和外国出生患者在实现初始病毒学抑制后病毒学失败率相似(风险比=1.54,95%置信区间:0.38 - 6.18;风险比=0.49,95%置信区间:0.11 - 2.20)。
我们的研究表明,艾伯塔省外国出生患者的ART治疗效果与加拿大出生的非原住民患者相似。然而,我们的结果表明,与加拿大出生的非原住民患者相比,加拿大出生的原住民患者的治疗效果较差。因此,临床医生、研究人员和社区成员必须更好地了解加拿大艾伯塔省北部加拿大出生的原住民患者ART治疗效果不佳的原因。